An addendum to "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma,” published in Journal for ImmunoTherapy of Cancer (JITC), is now available.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up to date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
Addendum v2.1 Summary
The information below provides an overview of addendum v2.1 to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma,” published in Journal for ImmunoTherapy of Cancer (JITC). The SITC Lung Cancer and Mesothelioma CPG Expert Panel has updated the recommendations in this guideline to address the following:
- On August 17, 2021, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA approved test, who have progressed on or following prior treatment and have no satisfactory alternative treatment options. The companion diagnostic, VENTANA MMR RxDx, was also approved to select patients with dMMR solid tumors for treatment with dostarlimab.
- On November 8, 2022, the US FDA approved cemiplimab in combination with platinum-based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ROS1 aberrations and is metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation.
- On November 10, 2022, the US FDA approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic NSCLC with no sensitizing EGFR mutation or ALK genomic tumor aberrations.
- On January 26, 2023, the US FDA approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- On October 16, 2023, the US FDA approved pembrolizumab as neoadjuvant treatment in combination with platinum-based chemotherapy, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) NSCLC.
- On May 16, 2024, the US FDA granted accelerated approval to tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
- On August 15, 2024, the US FDA approved durvalumab with platinum-based chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements.
- On September 17, 2024, the US FDA approved pembrolizumab with pemetrexed and platinum-based chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- On October 3, 2024, the US FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment followed by single-agent nivolumab as adjuvant treatment for adult patients with resectable NSCLC and no known EGFR mutations or ALK rearrangements.
- On December 4, 2024, the US FDA approved durvalumab as a single agent therapy for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
For More Information